AgomAb Therapeutics (NASDAQ:AGMB) Now Covered by Morgan Stanley

Morgan Stanley started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research note published on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $28.00 target price on the stock.

Separately, Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $32.00.

AgomAb Therapeutics Trading Down 1.9%

NASDAQ AGMB opened at $15.90 on Tuesday. AgomAb Therapeutics has a 12-month low of $12.66 and a 12-month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.